699 related articles for article (PubMed ID: 32046998)
1. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.
Spring LM; Fell G; Arfe A; Sharma C; Greenup R; Reynolds KL; Smith BL; Alexander B; Moy B; Isakoff SJ; Parmigiani G; Trippa L; Bardia A
Clin Cancer Res; 2020 Jun; 26(12):2838-2848. PubMed ID: 32046998
[TBL] [Abstract][Full Text] [Related]
2. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
Broglio KR; Quintana M; Foster M; Olinger M; McGlothlin A; Berry SM; Boileau JF; Brezden-Masley C; Chia S; Dent S; Gelmon K; Paterson A; Rayson D; Berry DA
JAMA Oncol; 2016 Jun; 2(6):751-60. PubMed ID: 26914222
[TBL] [Abstract][Full Text] [Related]
3. Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient's Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis.
Liu H; Lv L; Gao H; Cheng M
Comput Math Methods Med; 2021; 2021():7545091. PubMed ID: 35003324
[TBL] [Abstract][Full Text] [Related]
4. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
[TBL] [Abstract][Full Text] [Related]
5. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
Bonnefoi H; Litière S; Piccart M; MacGrogan G; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Moldovan C; Bodmer A; Zaman K; Cufer T; Campone M; Luporsi E; Malmström P; Werutsky G; Bogaerts J; Bergh J; Cameron DA;
Ann Oncol; 2014 Jun; 25(6):1128-36. PubMed ID: 24618153
[TBL] [Abstract][Full Text] [Related]
6. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
7. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
; Yee D; DeMichele AM; Yau C; Isaacs C; Symmans WF; Albain KS; Chen YY; Krings G; Wei S; Harada S; Datnow B; Fadare O; Klein M; Pambuccian S; Chen B; Adamson K; Sams S; Mhawech-Fauceglia P; Magliocco A; Feldman M; Rendi M; Sattar H; Zeck J; Ocal IT; Tawfik O; LeBeau LG; Sahoo S; Vinh T; Chien AJ; Forero-Torres A; Stringer-Reasor E; Wallace AM; Pusztai L; Boughey JC; Ellis ED; Elias AD; Lu J; Lang JE; Han HS; Clark AS; Nanda R; Northfelt DW; Khan QJ; Viscusi RK; Euhus DM; Edmiston KK; Chui SY; Kemmer K; Park JW; Liu MC; Olopade O; Leyland-Jones B; Tripathy D; Moulder SL; Rugo HS; Schwab R; Lo S; Helsten T; Beckwith H; Haugen P; Hylton NM; Van't Veer LJ; Perlmutter J; Melisko ME; Wilson A; Peterson G; Asare AL; Buxton MB; Paoloni M; Clennell JL; Hirst GL; Singhrao R; Steeg K; Matthews JB; Asare SM; Sanil A; Berry SM; Esserman LJ; Berry DA
JAMA Oncol; 2020 Sep; 6(9):1355-1362. PubMed ID: 32701140
[TBL] [Abstract][Full Text] [Related]
8. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.
Crosbie A; Le TK; Zhang Y; Das R; Ades F; Davis C; Gogate A
Future Oncol; 2023 Jan; 19(3):229-244. PubMed ID: 36974619
[TBL] [Abstract][Full Text] [Related]
11. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Kim MM; Allen P; Gonzalez-Angulo AM; Woodward WA; Meric-Bernstam F; Buzdar AU; Hunt KK; Kuerer HM; Litton JK; Hortobagyi GN; Buchholz TA; Mittendorf EA
Ann Oncol; 2013 Aug; 24(8):1999-2004. PubMed ID: 23562929
[TBL] [Abstract][Full Text] [Related]
12. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
13. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.
Fisher CS; Ma CX; Gillanders WE; Aft RL; Eberlein TJ; Gao F; Margenthaler JA
Ann Surg Oncol; 2012 Jan; 19(1):253-8. PubMed ID: 21725686
[TBL] [Abstract][Full Text] [Related]
15. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
[TBL] [Abstract][Full Text] [Related]
16. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
17. Real-World Outcomes Among Older Mexican Women with Breast Cancer Treated with Neoadjuvant Chemotherapy.
Cabrera-Galeana P; Soto-Perez-de-Celis E; Reynoso-Noveron N; Villarreal-Garza C; Lara-Medina F; Alvarado-Miranda A; Espinosa-Fernandez JR; Esparza-Arias N; Mohar A; Bargallo-Rocha JE
Oncologist; 2020 Dec; 25(12):1023-1031. PubMed ID: 32275801
[TBL] [Abstract][Full Text] [Related]
18. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
Shinde AM; Zhai J; Yu KW; Frankel P; Yim JH; Luu T; Kruper L; Vito C; Shaw S; Vora NL; Kirschenbaum M; Somlo G
Breast; 2015 Feb; 24(1):18-23. PubMed ID: 25467313
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
20. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
